Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

16
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
16
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

11
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

23
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
23
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

17
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
17
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

16
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
16

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The changing landscape of temporary mechanical circulatory support devices in the new heart allocation system: A US nationwide analysis.

JTCVS open·2026
Same author

Building bridges: Extracorporeal membrane oxygenation versus mechanical ventilation as bridge to lung transplant-A nationwide analysis.

JTCVS open·2026
Same author

Sex Differences in Heart Transplantation Outcomes: A 5-Year Review of the 2018 U.S. Allocation Policy.

JACC. Advances·2026
Same author

Longer travel distances and ischemic times with ex vivo lung perfusion in the Composite Allocation Score era: A nationwide analysis.

The Journal of thoracic and cardiovascular surgery·2026
Same author

Impact of renal function on survival in idiopathic pulmonary fibrosis patients 65 years and older undergoing lung transplantation in the United States.

JTCVS open·2026
Same author

Corrigendum to ''A multi-center analysis of lung transplantation outcomes comparing donation after circulatory death and donation after brain death'' [JHLT Open (2024) 100132].

JHLT open·2025

Related Experiment Video

Updated: Jul 20, 2025

Implantation of the Syncardia Total Artificial Heart
16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

35.3K

Right heart failure after left ventricular assist device implantation: a persistent problem.

Chesney Siems1, Rishav Aggarwal1, Andrew Shaffer1

  • 1Division of Cardiothoracic Surgery, Department of Surgery, University of Minnesota, 420 Delaware Street SE, MMC 207, Minneapolis, MN 55455 USA.

Indian Journal of Thoracic and Cardiovascular Surgery
|August 1, 2023
PubMed
Summary

Right heart failure (RHF) is a serious complication after left ventricular assist device (LVAD) implantation. This review explores RHF pathophysiology and treatment strategies for heart failure patients.

Keywords:
Adult cardiacLeft ventricular assist deviceMechanical circulatory supportRight heart failure

More Related Videos

Implantation of Total Artificial Heart in Congenital Heart Disease
07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

24.7K
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.7K

Related Experiment Videos

Last Updated: Jul 20, 2025

Implantation of the Syncardia Total Artificial Heart
16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

35.3K
Implantation of Total Artificial Heart in Congenital Heart Disease
07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

24.7K
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.7K

Area of Science:

  • Cardiology
  • Medical Devices
  • Heart Failure Research

Background:

  • Left ventricular assist devices (LVADs) are crucial for end-stage heart failure patients awaiting transplant or for destination therapy.
  • Right heart failure (RHF) is a significant complication post-LVAD implantation, associated with high morbidity and mortality.
  • Existing definitions of RHF vary, often involving the need for specific medical support or mechanical assistance for the right ventricle.

Purpose of the Study:

  • To review the complex pathophysiology of right heart failure (RHF) in the context of left ventricular assist device (LVAD) implantation.
  • To discuss current and emerging treatment strategies for managing RHF after LVAD.
  • To provide a comprehensive overview for clinicians and researchers in the field of advanced heart failure therapy.

Main Methods:

  • Literature review of studies on LVADs and RHF.
  • Analysis of pathophysiological mechanisms contributing to RHF.
  • Synthesis of clinical data on RHF management strategies.

Main Results:

  • RHF pathophysiology involves myocardial dysfunction, interventricular dependence, and increased right ventricular afterload.
  • Effective management requires addressing these underlying mechanisms.
  • Early identification and tailored treatment are key to improving outcomes.

Conclusions:

  • Right heart failure remains a critical challenge following LVAD implantation.
  • Understanding the multifactorial pathophysiology is essential for developing effective treatment protocols.
  • Further research into targeted therapies is needed to mitigate RHF complications and improve patient survival.